Results 31 to 40 of about 1,213 (150)

Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin [PDF]

Diabetes, Obesity and Metabolism, 2018
An integrated analysis was performed with data from 4 phase 2 and phase 3 studies of tofogliflozin in which patients with type 2 diabetes mellitus received the sodium‐glucose cotransporter 2 inhibitor tofogliflozin for up to 24 weeks. Sex differences, baseline haemoglobin A1c (HbA1c) and serum uric acid (UA) levels, and log
Motoshi Ouchi, Kenzo Oba, Kohei Kaku, Hideki Suganami, Akihiro Yoshida, Yasunori Fukunaka, Promsuk Jutabha, Asuka Morita, Naoyuki Otani, Keitaro Hayashi, Tomoe Fujita, Tatsuya Suzuki, Masahiro Yasutake, Naohiko Anzai   +13 more
openaire   +2 more sources

Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus

Journal of Diabetes Research, 2018
Sodium-glucose cotransporter 2 inhibitor tofogliflozin is a new type of antidiabetic drug for individuals with type 2 diabetes mellitus (T2DM). The aim of this study was to examine in which type of individuals and/or under which conditions tofogliflozin ...
Shinji Kamei, Masahiro Iwamoto, Miyuki Kameyama, Masashi Shimoda, Tomoe Kinoshita, Atsushi Obata, Tomohiko Kimura, Hidenori Hirukawa, Fuminori Tatsumi, Kenji Kohara, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto   +13 more
doaj   +1 more source

Effect of Tofogliflozin on Skeletal Muscle Mitochondrial Function in Male Diabetic Mice With Muscle Atrophy. [PDF]

J Endocr Soc
Abstract Sodium-glucose cotransporter-2 (SGLT2) inhibitors are effective medications for type 2 diabetes (T2D), chronic kidney disease, and chronic heart failure regardless of diabetic status. However, concerns remain about their potential to reduce skeletal muscle mass.
Kishida C, Murakoshi M, Sakuma H, Shibata T, Suzuki Y, Gohda T.   +5 more
europepmc   +4 more sources

Therapeutic potential of tofogliflozin on nephrotic syndrome secondary to diabetic nephropathy [PDF]

Journal of Cardiology Cases, 2017
Diabetic nephropathy (DN) is a critical complication in patients with type 2 diabetes and regarded as a progressive disorder with a poor prognosis. The degree of albuminuria is associated closely with worse renal and cardiovascular outcomes. It is therefore important to achieve remission of proteinuria to avoid progression of DN and improve outcomes ...
Atsushi Tanaka, Tsukasa Nakamura, Eiichi Sato, Koichi Node   +3 more
openaire   +2 more sources

Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A subanalysis of a post‐marketing study (J‐STEP/EL Study)

Journal of Diabetes Investigation, 2020
Aims/Introduction This subanalysis aimed to assess the safety and effectiveness of tofogliflozin by using data from the Japanese Study of Tofogliflozin with Type 2 Diabetes Mellitus Patients in an Observational Study of the Elderly to categorize elderly ...
Kohei Kaku, Yusuke Naito, Masayuki Senda, Yuji Kurihara, Ryoji Gunji, Seigo Kakiuchi, Kazunori Utsunomiya   +6 more
doaj   +1 more source

Multicenter, Open Label, Randomized Controlled Superiority Trial for Availability to Reduce Nocturnal Urination Frequency: Study Protocol for a TOP-STAR Study

Diabetology, 2022
Nocturia is a common disease in patients with type 2 diabetes mellitus that can reduce the quality of life. Sodium glucose co-transporter 2 (SGLT2) inhibitors increase the urine volume and are often discontinued when polyuria occurs, although ...
Hanako Nakajima, Hiroshi Okada, Akinori Kogure, Takafumi Osaka, Takeshi Tsutsumi, Toru Tanaka, Goji Hasegawa, Shinichi Mogami, Kazuteru Mitsuhashi, Noriyuki Kitagawa, Yoshitaka Hashimoto, Miho Yano, Muhei Tanaka, Akane Kitamura, Michiyo Ishii, Naoto Nakamura, Akio Kishi, Emi Ushigome, Masahide Hamaguchi, Michiaki Fukui   +19 more
doaj   +1 more source

Effects of Tofogliflozin on Cardiac Function in Elderly Patients With Diabetes Mellitus

Journal of Clinical Medicine Research, 2020
Patients with type 2 diabetes mellitus (T2DM) are at increased risk for impairments in diastolic relaxation and heart failure with preserved ejection fraction (EF). Recent clinical data suggest that several sodium glucose transporter-2 (SGLT2) inhibitors are found to reduce cardiovascular disease (CVD) events in elderly diabetic patients, but the ...
Higashikawa, Toshihiro, Ito, Tomohiko, Mizuno, Takurou, Ishigami, Keiichirou, Kohori, Masaru, Mae, Kunihiro, Usuda, Daisuke, Takagi, Susumu, Sangen, Ryusho, Saito, Atsushi, Iguchi, Masaharu, Kasamaki, Yuji, Fukuda, Akihiro, Kanda, Tsugiyasu, Okuro, Masashi   +14 more
openaire   +3 more sources

The Influence of Tofogliflozin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus [PDF]

Diabetes Therapy, 2021
Treatment-related quality of life (QOL) is an important aspect of diabetes management. We evaluated the influence of a sodium-glucose cotransporter 2 (SGLT2) inhibitor, tofogliflozin, on treatment-related QOL in Japanese patients with type 2 diabetes mellitus (T2DM).This is the prespecified subanalysis study of the "Using TOfogliflozin for Possible ...
Naoto Katakami, Tomoya Mita, Hidenori Yoshii, Toshihiko Shiraiwa, Tetsuyuki Yasuda, Yosuke Okada, Keiichi Torimoto, Yutaka Umayahara, Hideaki Kaneto, Takeshi Osonoi, Tsunehiko Yamamoto, Nobuichi Kuribayashi, Kazuhisa Maeda, Hiroki Yokoyama, Keisuke Kosugi, Kentaro Ohtoshi, Isao Hayashi, Satoru Sumitani, Mamiko Tsugawa, Kayoko Ryomoto, Hideki Taki, Tadashi Nakamura, Satoshi Kawashima, Yasunori Sato, Hirotaka Watada, Iichiro Shimomura, I. Hayashi, M. Tsugawa, H. Yokoyama, H. Yoshii, K. Komiyama, T. Mita, T. Shimizu, T. Yamamoto, S. Kawashima, T. Nakamura, S. Kamei, T. Kinoshita, M. Shimoda, K. Maeda, K. Kosugi, H. Yoshii, H. Ishida, T. Osonoi, M. Saito, A. Tamazawa, S. Sumitani, N. Fujiki, Y. Fujita, S. Shimizu, Y. Umayahara, K. Kato, Y. Irie, R. Kataoka, T. Yasuda, Y. Kiyohara, M. Ohashi, K. Ryomoto, Y. Takahi, Y. Fujishima, Y. Fujita, A. Fukuhara, K. Fukui, Y. Hosokawa, A. Imagawa, H. Iwahashi, K. Mukai, N. Katakami, T. Katsura, D. Kawamori, T. Kimura, S. Kobayashi, J. Kozawa, F. Kubo, N. Maeda, T. Matsuoka, K. Miyashita, S. Nakata, H. Ninomiya, H. Nishizawa, Y. Okuno, M. Otsuki, F. Sakamoto, S. Sasaki, I. Sato, N. Shimo, I. Shimomura, M. Takahara, T. Takano, A. Tokunaga, S. Uno, M. Yamaoka, S. Yoneda, K. Ohtoshi, T. Shiraiwa, M. Hajime, K. Koikawa, F. Kuno, A. Kurozumi, K. Matsushita, M. Narisawa, K. Tanaka, K. Sugai, Y. Okada, K. Torimoto   +104 more
openaire   +2 more sources

Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study)

Contemporary Clinical Trials Communications, 2020
Background: The incidence of nonalcoholic fatty liver disease (NAFLD) has increased recently and is related to obesity and the associated surge in type 2 diabetes mellitus (DM) and metabolic syndrome diagnoses.
Anna Ozaki, Masato Yoneda, Takaomi Kessoku, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Eiji Sakai, Masataka Taguri, Takeharu Yamanaka, Tomoyuki Iwasaki, Takeo Kurihashi, Satoru Saito, Atsushi Nakajima   +14 more
doaj   +1 more source

Changes in the estimated glomerular filtration rate and predictors of the renal prognosis in Japanese patients with type 2 diabetes: A retrospective study during the 12 months after the initiation of tofogliflozin.

PLoS ONE, 2023
BackgroundThe changes in the estimated glomerular filtration rate (eGFR) and predictors of the renal prognosis were retrospectively assessed over the 12 months after the initiation of tofogliflozin, which has the shortest half-life among sodium-glucose ...
Hiroyuki Ito, Hideyuki Inoue, Takuma Izutsu, Suzuko Matsumoto, Shinichi Antoku, Tomoko Yamasaki, Toshiko Mori, Michiko Togane   +7 more
doaj   +1 more source